Prostate Cancer: KOL Insight 2016

Maximum Purchase:
1 unit
Publication Date:
October 2016
Adding to cart… The item has been added

Latest Update

Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib] and Clovis Oncology’s rucaparib) that are in Phase III development for men with metastatic castration-resistant prostate cancer (mCRPC). KOLs also provide their first insights on the IMbassador250 Phase III study that was initiated in January 2017 investigating Roche’s anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor Tecentriq (atezolizumab) in combination with Xtandi (enzalutamide) in patients with mCRPC. With Bavarian Nordic’s PROSPECT study due to complete in 2017, KOLs also discuss their expectations for the highly-anticipated study investigating the vaccine PROSTVAC (rilimogene galvacirepvec-rilimogene glafolivec) (PSA-TRICOM) in prostate cancer.

*Latest* Update 2: April 2017
Update 1: January 2017
Original Publication: Oct 2016
*Purchase of this report includes all updates*

This update tackles these key questions

  • How do KOLs view the biomarker-driven data published for AstraZeneca’s olaparib in prostate cancer?
  • What are KOL expectations for olaparib and rucaparib in patients with mCRPC and how do the drugs compare?
  • Which treatment settings do KOLs expect PARP inhibitors to gain traction?
  • How do the experts view the PD-L1 inhibitor drug class in prostate cancer?
  • How does atezolizumab compare with other PD-1/PD-L1 immune checkpoint inhibitors such as Merck & Co.’s Keytruda (pembrolizumab)?
  • What are KOL expectations for the Phase III IMbassador250 study with Roche’s atezolizumab?
  • Where will immunotherapy combinations be best utilised in patients with prostate cancer?
  • What are KOL expectations for Bavarian Nordic’s PROSPECT study with the PROSTVAC vaccine?
  • How does PROSTVAC compare to Provenge and what are the key advantages of vaccine treatment?

Update 1

Gain new KOL insights on the latest events happening in prostate cancer (PC). In December 2016, Pfizer and Astellas Pharmaceuticals announced the Phase IV PLATO study, evaluating continued treatment with Xtandi plus Zytiga and prednisone as compared to treatment with Zytiga and prednisone alone, did not meet its primary endpoint of improvement in progression-free survival (PFS) in patients with chemotherapy-naïve castration-resistant PC whose PSA has previously progressed on Xtandi. Astellas also presented new data at the 2016 ESMO Congress, reaffirming the role of Xtandi in extending time to PSA progression in men with advanced PC; the study examined the efficacy and safety of enzalutamide versus placebo in 409 Asian patients. Plus, the ongoing development of vaccines in combination with immune checkpoint inhibitors, including Madison Vaccine’s MVI-816 with Merck & Co’s Keytruda and Bavarian Nordic’s PROSTVAC with BMS’ Yervoy, is discussed.

Original Publication: PARP inhibitors and second-generation hormonal therapies driving KOL excitement

Good news for late-stage prostate cancer patients: a host of new therapies are in the pipeline, indications for mainstay drug classes are expanding, and personalized treatment may be just around the corner. Find out how doctors and manufacturers are dealing with a fast-evolving treatment algorithm and more intense competition in KOL Insight: Prostate Cancer.

Twelve North American and European KOLs’ weigh in on the near-term outlook for 5 marketed prostate cancer treatments and 14 more currently in the pipeline. Learn whether hormonal therapies will move into earlier settings, whether bone-targeted therapies will see wider use in combination, whether new immunotherapies will outperform first-generation predecessors, whether PARP inhibitors offer real hope for personalized medicine, and more.

Request sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends

See the Top Takeaways >

 “We have to focus now on how to better select our patients and to better understand the disease and make treatment strategies and treatment sequences really adapted on a per patient basis in terms of selection. I think that is the key.”
US Key Opinion Leader

Sample of therapies covered:

  • Xtandi (enzalutamide; Astellas/Medivation)
  • Zytiga (abiraterone acetate; Johnson & Johnson)
  • Apalutamide (ARN-509/JNJ-927; Johnson & Johnson)
  • Lynparza (olaparib; AstraZeneca)
  • Prostvac (rilimogene galvacirepvec/rilimogene glafolivec; Bavarian Nordic/Bristol-Myers Squibb)
  • Plus 14 more - download the full list now >

Sample of KOLS interviewed

  • Andrew J Armstrong. Associate Professor of Medicine and Surgery and Medical Oncologist at Duke University and the Duke Cancer Institute, Durham, NC.
  • Tomasz M Beer. Professor, Division of Hematology and Medical Oncology and Deputy Director, Oregon Health & Science University Knight Cancer Institute, Portland, OR.
  • David E Crawford. Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado, Aurora, CO.
  • Daniel P Petrylak. Professor of Medicine (Medical Oncology) and Urology at Yale School of Medicine, New Haven, CT.
  • Chris Parker. Senior Lecturer and Honorary Consultant in Clinical Oncology and Prostate Cancer Translational Research at The Institute of Cancer Research and The Royal Marsden, London, UK.
  • Plus 7 more – download the full list now >

Top Takeaways

  • Kick-starting personalized medicine: when it comes to personalizing treatment, prostate cancer lags behind other malignancies. Now KOLs think that Lynparza and other PARP inhibitors could change that. What’s driving their optimism?
  • Hormonal therapies to see earlier use: Next-generation hormonal therapies like Xtandi, Zytiga, and apalutamide are moving up the treatment algorithm. What are the most promising indications for these drugs, and what effect do KOLs expect to see on overall survival (OS)?
  • Key differentiators needed: With so many Phase III trials of hormonal therapies ongoing, KOLs anticipate stiff competition. What are the three key factors that will do the most to differentiate new market entrants?
  • Potential for Bone-Targeted Therapy Combinations: A handful of clinical trials evaluating combinations of bone-targeted therapies and other agents are underway. Could the results push bone-targeted therapies up the treatment algorithm?
  • Outlook unclear for new immunotherapies: An underwhelming performance by Provenge has lowered expectations for vaccines and immunotherapies in prostate cancer treatment. Will Prostvac and other new options in the pipeline fare better?
  • Earlier use of chemotherapy: In the wake of the STAMPEDE and CHAARTED trials, chemotherapy is being used earlier in the treatment algorithm. Do KOLs expect this trend to continue?
  • Endpoint shuffle: KOLs have concerns about continued use of OS as an endpoint for clinical trials, but what’s the alternative? Do they consider metastases free survival (MFS) to be a valid predictor of OS and an approvable endpoint?
  • Future of the treatment algorithm hinges on key trials: Get KOLs Thoughts on over 20 ongoing or recently completed clinical trials including EMBARK, PROSPER, PRESIDE, ENZAMET, ENZARAD, PEACE 1, SPARTAN, ATLAS, TITAN, TOPARP-A, and others.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.